Glucagon-like peptide-1 (GLP-1) analogues

2 Drugs classified under this drug class

Glucagon-like peptide-1 (GLP-1) analogues. Semaglutide 1.34 mg/ml.
PREF. PEN: 1×1.5, 3 ml, 3×1.5, 3 ml. Init. dose is 0.25 mg once wkly. After 4 wks. the dose should be incr. to 0.5 mg once wkly. After at least 4 wks. with a dose of 0.5 mg once wkly., the dose can be incr. to 1 mg once wkly. to further improve glycaemic control. Semaglutide 0.25 mg is not a mainten.dose. Wkly. doses higher than 1 mg are not recomm.
When Ozempic is added to existing metformin and/or thiazolidinedione ther., the current dose of metformin and/or thiazolidinedione can be cont. unchanged.
When Ozempic is added to existing ther. of sulfonylurea or insulin, a reduction in the dose of sulfonylurea or insulin should be consid. to reduce the risk of hypoglyc. Self-monitor. of blood glucose is not need. in order to adjust the dose of Ozempic.
Miss. dose should be admin.as soon as possible and within 5 d. after the miss. dose. If more than 5 d. have pass., the miss.  dose should be skipped, and the next dose should be admin. on the regularly scheduled day. In each case, pts. can then resume their regular once wkly. dosing schedule. See lit.
Tmt. of adults with insuffic. control. type 2 diabet. mell. as an adjunct to diet and exercise. As monother. when metformin is consid. inappropr. due to intoler. or contraindications. In addition to other medicinal products for the tmt. of diabetes.
For study results with respect to combinat., effects on glycaemic control and cardiovasc. events, and the populations studied.
C/I: Hypersens.